Quarterly report [Sections 13 or 15(d)]

Schedule of Segment Financial Information (Details)

v3.25.3
Schedule of Segment Financial Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue from External Customer [Line Items]                
Personnel related $ 504,387     $ 2,401,359     $ 2,403,363 $ 6,011,201
Total research and development 504,387     2,401,359     2,403,363 6,011,201
Total selling, general and administrative 1,256,284     824,294     3,469,842 3,301,753
Interest income 68,682     52,497     176,536 176,431
Net loss (1,691,989) $ (1,701,093) $ (2,303,587) (3,173,156) $ (2,829,106) $ (3,134,262) (5,696,669) (9,136,523)
Clinincal [Member]                
Revenue from External Customer [Line Items]                
Personnel related     1,920,092     705,645 4,359,819
Total research and development     1,920,092     705,645 4,359,819
Chemistry Manufacturing and Controls [Member]                
Revenue from External Customer [Line Items]                
Personnel related 36,274     127,781     320,104 346,273
Total research and development 36,274     127,781     320,104 346,273
Personnel Related [Member]                
Revenue from External Customer [Line Items]                
Personnel related 468,113     353,486     1,377,614 1,305,109
Total research and development 468,113     353,486     1,377,614 1,305,109
Total selling, general and administrative 307,841     261,517     1,005,226 1,153,826
Public Company Compliance [Member]                
Revenue from External Customer [Line Items]                
Total selling, general and administrative 475,503     562,777     1,991,676 2,147,927
Marketing Expense [Member]                
Revenue from External Customer [Line Items]                
Total selling, general and administrative $ 472,940         $ 472,940